Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | RYR1 | P21817 | 1/20 | 0.35 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13998057 | 0.87 | RYR1 (0.37) | PTPN1RYR1TLR4 | |
| SCHEMBL13998101 | 0.83 | ABCB1 (0.40) | PTPN1TLR4 | |
| SCHEMBL13998090 | 0.82 | PTPN1 (0.41) | PTPN1TLR4POLBCTDSP1 | |
| SCHEMBL13998106 | 0.81 | RYR1 (0.33) | PTPN1RYR1 | |
| SCHEMBL13998094 | 0.81 | KMT2A (0.40) | PTPN1 | |
| SCHEMBL13998100 | 0.81 | PTPN1 (0.37) | PTPN1TLR4POLBCTDSP1 | |
| SCHEMBL13998095 | 0.80 | KMT2A (0.39) | PTPN1TLR4POLB | |
| SCHEMBL13998102 | 0.80 | PTPN1 (0.36) | PTPN1TLR4POLBCTDSP1 | |
| SCHEMBL13998091 | 0.79 | PTPN1 (0.39) | PTPN1TLR4POLBCTDSP1 | |
| SCHEMBL13998092 | 0.78 | PTPN1 (0.38) | PTPN1TLR4POLBCTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | CALECO PHARMA CORP. | 2008-12-25 | — | — | US | disclosed |
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | CALECO PHARMA CORP. | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | HCCS, HAVCR2, PYGL | PTPN1 3880/4885RYR1 4531/4885TLR4 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.